BOCA RATON, Fla., July 12, 2019 (GLOBE NEWSWIRE) -- The advancement of digital technology has dramatically changed the audience for eye health and long-term associated risk of retinal damage from conditions such as macular degeneration. Once thought to be a health issue only for older adults, children may be at risk of higher damage since their eyes absorb more blue light than adults. Twinlab Consolidated Holdings, Inc. (OTCPK:TLCC) (“TCC” or “Twinlab”) has developed a gummy supplement with clinically studied ingredients for both adults and children called Blutein Gummies, designed to protect eyes of all ages from potentially harmful blue light damage, which are the wavelengths emitted from device screens.
On average most adults spend 10.5 hours in front of a screen, while children average 6.5 hours of screen time a day. Blue light is emitted from smartphones, computers, televisions, tablets, artificial light and even sunlight. Laboratory studies have shown that too much exposure to blue light can damage light-sensitive cells in the retina, which could lead to vision problems and interfere with natural sleep and wake cycles. Macular degeneration is the deterioration of the macula, the small central area of the eye’s retina that controls detailed vision such as facial recognition, fine reading, computer use and television watching. The macula can be protected from blue light by limiting screen time and sunlight by using sunglasses.
“Short-term effects of blue light related to digital eyestrain can cause dry eyes, blurred vision, eyestrain, fatigue, increased frequency of headaches and difficulty sleeping, but long-term effects may risk damage to delicate retinal cells leading to vision problems like age-related macular degeneration,” said Dr. Rudrani Banik, a board-certified ophthalmologist specializing in integrative approaches to vision health. “We live in a digital world and are constantly exposed to more and more screen time and children may be at higher risk of blue light retinal damage than adults.”
A published study estimates that 50% or more of computer users experience symptoms of digital eyestrain with six or more hours of daily digital device use. According to one study, a child’s lens absorbs less short-wavelength light than the adult lens, allowing more blue light to reach a child’s retina. Generation Z (those born after 1995) will be the first generation to have been exposed to digital devices their entire lifetime. Banik says this could be problematic since the long-term consequences of blue light exposure in children are not well understood.
Studies suggest that nutrition can also play a protective role in eye health. Lutein and zeaxanthin are two carotenoids from the beta-carotene family that are found in high concentration in parts of the retina where they help protect the eye against blue light. By absorbing the blue light, these carotenoids protect the retina by acting as a nutritional filter of blue light.
“Lutein and zeaxanthin are two very important nutrients that we simply do not get enough of through our regular diet,” said Banik, who runs Envision Health NYC, a concierge practice specializing in eye health, neurological conditions, and migraine headaches. “Supplementing with 10-20 mg of lutein and 2-4 mg of zeaxanthin isomers is important for protective eye health and visual eyestrain in both children and adults.”
Twinlab Ocuguard Blutein Gummies for adults and children use the clinically studied lutein and zeaxanthin isomers, Lutemax2020, sourced from marigold flower extract. In studies, it has been shown to reduce eye fatigue and strain, in addition to increasing the amount of optical pigment density. Blutein Gummies are tasty, making it easy to take for children and adults. They do not contain high fructose corn syrup, artificial flavors or gluten. They are vegan and pectin based (versus gelatin based). Now available at Walgreens and other retailers online and in-store, the recommended dose for children is one gummy per day and two gummies per day for adults. Suggested retail price on both supplements is $24.99 (60-count bottle). Learn more at: https://twinlab.tlcchealth.com/blutein/.
About Twinlab Consolidated Holdings, Inc.
Twinlab Consolidated Holdings, Inc. (“TLCC”) is the parent holding company of Twinlab Consolidation Corp., an industry-focused health and wellness company committed to developing top brands. TLCC has a portfolio of products that are made in America using the finest ingredients from around the world. In addition to its namesake brand, Twinlab®, established in 1968, TLCC, through TCC and its subsidiaries, also manufactures and sells other well-known category leaders including the Metabolife® line of diet and energy products; the Twinlab® Fuel line and newly launched REAAL® sports nutrition products; Alvita® teas, established in 1922 as a single-herb tea line; and premium nutritional and anti-aging/wellness supplements under the award winning Reserveage™ Nutrition family of brands. TCC also owns NutraScience Labs, an award-winning contract manufacturer. Visit www.tchhome.com for more information.
Forward Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, those risks set forth in the “Item 1A. Risk Factors” section of the Annual Report for the year ended December 31, 2018 on Form 10-K filed by TLCC with the Securities and Exchange Commission on April 16, 2019 as updated by TLCC's other SEC filings. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Photos accompanying this announcement are available at
CONTACT: Media Contact: Amy Summers 212-757-3419 or firstname.lastname@example.org Pitch Publicity
© 2019 GlobeNewswire, Inc. All Rights Reserved.
Relmada Therapeutics (Nasdaq: RLMD) Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
**Disclaimer: Crown Equity Holdings Inc. has received $5,000.00 (five thousand dollars) in cash from Nass Valley Gateway Ltd. (CSE:NVG) (FSE:3NVN) for 30 days of advertisement services